Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3016% below fair value
$1.84−0.03 (-1.60%)
Close on Nov 20, 2026Market cap $145.59MP/E 15.3Yield –
Niagen Bioscience free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Niagen Bioscience's free cash flow for the twelve months ending Sep 30, 2020 was -$11.66M. For fiscal 2019 it was -$21.18M. The highest annual figure on record is -$2.64M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | -$21.18M | – |
| FY2018 | Dec 31, 2018 | -$22.23M | – |
| FY2017 | Dec 30, 2017 | -$10.97M | – |
| FY2016 | Dec 31, 2016 | -$4.44M | – |
| FY2015 | Jan 2, 2016 | -$2.64M | – |
| FY2014 | Jan 3, 2015 | -$2.70M | – |
| FY2013 | Dec 28, 2013 | -$4.04M | – |
| FY2012 | Dec 29, 2012 | -$10.14M | – |
| FY2011 | Dec 31, 2011 | -$4.25M | – |
| FY2010 | Jan 1, 2011 | -$2.83M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2020 | Sep 30, 2020 | -$3.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.65M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.24M | – |
| Q4 FY2019 | Dec 31, 2019 | -$890.00K | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.92M | – |
| Q2 FY2019 | Jun 30, 2019 | -$9.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.15M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.27M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.66M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.15M | – |
| Q4 FY2017 | Dec 30, 2017 | -$4.06M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$372.76K | – |
| Q3 FY2016 | Oct 1, 2016 | -$850.17K | – |
See a number that looks wrong?